Daily MedNews
Printable Version   Email to a friend

Health Highlights: July 23, 2008

Here are some of the latest health and medical news developments, compiled by editors of HealthDay:

Experts Worried Over Rising HIV Rates Among U.S. Hispanics

Increasing rates of HIV/AIDS among Hispanics in the United States point to a simmering public health crisis, experts tell the Washington Post.

Hispanics make up about 14 percent of the U.S. population, but they accounted for 22 percent of new HIV/AIDS diagnoses in 2006. In major American cities, as many as one in four gay Hispanic men have HIV, a rate similar to that in sub-Saharan Africa, the Post reported.

Hispanics in Washington, D.C. have the highest rate of new AIDS cases in the United States, according to a Kaiser Family Foundation survey.

Language and cultural barriers are among the issues that pose a challenge to dealing with HIV/AIDS in the Hispanic community, the Post reported. Legal status is another issue. For illegal Hispanic immigrants, fear of arrest and deportation is a major obstacle to seeking diagnosis and treatment.

-----

Millions Sought for AIDS Treatment in Africa

A campaign to raise $21 million to fund an AIDS treatment program in five African countries has been launched by the International Federation of Red Cross and Red Crescent Societies (IFRC).

The money would be used for a three-year program in Burkina Faso, the Central African Republic, the Democratic Republic of Congo, Guinea and Nigeria. The program would reach 950,000 vulnerable people, including 49,000 people living with AIDS, 13,000 sex workers and 10,000 orphans, Agence France-Presse reported.

According to the IFRC, nearly 4.5 million people, including about 400,000 children younger than 14, are living with HIV in the five countries. In 2006, AIDS claimed the lives of 350,000 people in these countries, which form the Sahel region of west and central Africa.

"Even though the impact may vary from one country to another, HIV is a major obstacle to development as it affects all key sectors: the economy, health, education and even food security," said Abdourahmane Ndiaye, IFRC's HIV program officer for the region, AFP reported.

-----

Study Examining High Cancer Incidence in U.S. South

Researchers plan to recruit 90,000 people in 12 Southern states in an effort to learn why the South has become the cancer belt of the United States and why blacks have higher rates of several kinds of cancer, United Press International reported.

Brain cancer and lung cancer are among those that disproportionately affect people living in the South.

"When you look at a map of brain cancer incidence in the United States the Southeast just lights up in red," Dr. Reid Thompson, of Vanderbilt-Ingram Cancer Center in Nashville said in a news release.

The researchers will look at study participants' lifestyles, family medical histories and risk factors for cancer and other serious diseases, UPI reported.

"We're asking patients about their diets, possible job-related exposure to cancer causing chemicals, and we're collecting DNA samples," Thompson said.

-----

Plant-Based Cancer Vaccine Shows Promise

A plant-based cancer vaccine that kick-starts the immune system and can be tailored to target specific tumor types shows promise, according to U.S. researchers who tested the vaccine on 16 people with incurable follicular B-cell lymphoma.

More than 70 percent of the patients developed an immune response and none of them showed any significant side effects, Agence France-Presse reported. The study appears in the journal Proceedings of the National Academy of Sciences.

"The idea is to marshal the body's own immune system to fight cancer," said study senior author Ronald Levy of the Stanford Medical Center. "We know that if you get the immune system revved up, it can attack and kill cancer."

He and his colleagues are the first to test a plant-based cancer vaccine on people, AFP reported. It's not yet clear whether the immune response triggered by the vaccine is sufficient to destroy cancer.

-----

New Drug Seems Effective Against Aggressive Prostate Cancer

A new drug called abiraterone may prove to be a breakthrough treatment for aggressive prostate cancer. Scientists say the drug -- which blocks hormones that fuel the cancer -- could potentially treat up to 80 percent of patients with a deadly form of the disease that's resistant to chemotherapy, BBC News reported.

A study of 21 patients with advanced, aggressive prostate cancer treated with the drug found significant tumor shrinkage and a decline in levels of a key protein produced by the cancer. Many patients reported a significant improvement in their quality of life, and some were able to stop taking morphine to ease the pain caused by the spread of the cancer into their bones.

The findings appear in the Journal of Clinical Oncology.

"We believe we have made a major step forward in the treatment of end-stage prostate cancer patients," according to lead researcher Dr. Johann de Bono, who was quoted by BBC News.

"These men have very aggressive prostate cancer which is exceptionally difficult to treat and almost always proves fatal. We hope that abiraterone will eventually offer them real hope of an effective way of managing their condition and prolonging their lives," de Bono said.

Currently, the drug is being assessed in an advanced clinical trial involving 1,200 patients around the world, BBC News reported.

-----

South Korea Begins Year-Round Bird Flu Monitoring

South Korea plans to establish about 23 teams to conduct year-round monitoring for bird flu, the agriculture ministry said Tuesday. The decision comes after the country experienced its worst bird flu outbreak, which led to the slaughter of more than 8 million domestic birds.

As part of the new program, migratory and resident wild birds will be monitored regularly and all chicken and duck farms will be inspected every other week for strains of bird flu, Agence France-Presse reported.

Until now, South Korea went on heightened bird flu alert from November to March, when migratory birds stay in the country and weather conditions can promote the spread of bird flu. But this year, an outbreak began in early April and spread through most of the country.

Even though the country has had three major bird flu outbreaks, no person in South Korea is known to have contracted the disease, AFP reported. Worldwide, the H5N1 bird flu virus has killed more than 240 people since 2003.


Latest Daily MedNews...

Daily MedNews Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jul | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
October 9, 2008
Audience: Pediatric and primary healthcare professionals, consumers [Posted 10/09/2008] FDA notified healthcare professionals and...
October 7, 2008
Audience: Pulmonary care health professionals and patients[UPDATE 10/07/2008] FDA informed healthcare professionals that FDA has...
October 3, 2008
Audience: Healthcare professionals, consumers [Posted 10/03/2008] FDA notified healthcare professionals of a Class I Recall of...
October 2, 2008
Audience: Physical medicine and rehabilitation specialists, anesthesia healthcare professionals, hospital surgical service...
More...
Latest Drug Information Updates

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

Navstel
Navstel is a balanced salt ophthalmic solution for use as an intraocular irrigation during surgical procedures involving perfusion of the eye.

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

More...